The Rubicon Research IPO will open on October 9, 2025, and close on October 13, 2025. It is a Book Built Issue through which the company aims to raise approximately ₹1,377.50 crores. This includes a fresh issue of ₹500 crores and an offer for sale of up to 1,80,92,762 equity shares, each having a face value of ₹1.

The price band for the IPO is set at ₹461 to ₹485 per share. The issue allocation is divided into 75% for QIBs, 15% for HNIs, and 10% for retail investors. The IPO is proposed to be listed on the BSE and NSE on October 16, 2025, with the allotment date scheduled for October 14, 2025.

Looking at its financials, the company reported revenue of ₹1,296.22 crores in 2025, compared to ₹872.39 crores in 2024. Its profit rose to ₹134.36 crores in 2025, up from ₹91.01 crores in 2024. Based on this growth, investors may consider subscribing to the IPO with a long-term investment perspective.

About Rubicon Research IPO

We are a pharmaceutical formulations company delivering value to our customers and investors by developing, manufacturing, and marketing branded specialty and generic prescription pharmaceutical products. We commenced operations in 1999 as a provider of contract formulation development services to pharmaceutical companies. We operationalized our oral solids manufacturing facility at Ambernath, Maharashtra, India in 2011 and expanded our service offering to contract development and manufacturing services for products intended for regulated markets. In 2012, we changed focus from providing contract services to developing, manufacturing, and commercializing our own products in the US market.
We carry out product development activities at two facilities – our principal R&D facility is located in Thane, Maharashtra, India where we develop multiple dosage forms and product categories, and our development center for inhalation and nasal products is located in Ontario, Canada. Our two US FDA-inspected pharmaceutical manufacturing facilities, both located in Maharashtra, India, are together capable of producing oral solid dose products, oral liquid products, as well as unit-dose, bi-dose, and multi-dose nasal spray products in an environment of US cGMP. Our facilities are also accredited with other regulators including the MHRA UK, Health Canada and TGA among others.